Trends in expenditures for Medicare liver transplant recipients
- 1 October 2001
- journal article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 7 (10) , 858-862
- https://doi.org/10.1053/jlts.2001.27868
Abstract
Liver transplantation, a resource-intensive medical procedure, is under particular scrutiny in the current era of cost containment. There have been significant changes in treatment protocols over the past decade; however, information is limited on how these changes have affected the economics of liver transplantation. This study examines a time series from 1993 to 1999 in Medicare expenditures for liver transplantation. We estimated total first- and second-year expenditures, as well as expenditures 90 days pretransplantation. These expenditures included inpatient, outpatient, physician, home health, and hospice care; immunosuppression expenditures were not estimated. Average first-year expenditures (in year 2000 dollars) for liver transplantation, excluding immunosuppressives, decreased from $201,677 in 1993 to $143,363 in 1998. Inpatient costs accounted for the majority of total expenditures, decreasing from $179,306 in 1993 to $120,445 in 1998. Total days of hospitalization decreased from 56.7 days in 1993 to 42.2 days in 1998. The majority of hospitalization occurred during the first 90 days posttransplantation, but decreased from 44.4 days in 1993 to 29.4 days in 1999. Substantial cost reductions over this period were a result of reduced hospitalization and occurred while survival rates gradually improved.Keywords
This publication has 13 references indexed in Scilit:
- PROLONGATION OF CANINE LIVER ALLOGRAFT SURVIVAL BY A NOVEL IMMUNOSUPPRESSANT, FTY720Transplantation, 2000
- SIROLIMUS: A POTENT NEW IMMUNOSUPPRESSANT FOR LIVER TRANSPLANTATIONTransplantation, 1999
- A LONG-TERM COMPARISON OF TACROLIMUS (FK506) VERSUS CYCLOSPORINE IN LIVER TRANSPLANTATION1Transplantation, 1998
- Predictors of the cost of liver transplantationLiver Transplantation and Surgery, 1998
- Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal TransplantationNew England Journal of Medicine, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- THE IMPACT OF IMMUNOSUPPRESSIVE REGIMENS ON THE COST OF LIVER TRANSPLANTATION—RESULTS FROM THE U.S. FK506 MULTICENTER TRIALTransplantation, 1995
- Liver TransplantationNew England Journal of Medicine, 1989
- Liver TransplantationNew England Journal of Medicine, 1989
- Liver transplantation in adultsGastroenterology, 1986